{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,25]],"date-time":"2026-08-25T03:58:43Z","timestamp":1787630323832,"version":"build-2736575974"},"reference-count":98,"publisher":"Elsevier BV","issue":"6","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"funder":[{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["K24AR063120"],"award-info":[{"award-number":["K24AR063120"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000069","name":"National Institute of Arthritis and Musculoskeletal and Skin Diseases","doi-asserted-by":"publisher","award":["AR007080"],"award-info":[{"award-number":["AR007080"]}],"id":[{"id":"10.13039\/100000069","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Seminars in Arthritis and Rheumatism"],"published-print":{"date-parts":[[2021,12]]},"DOI":"10.1016\/j.semarthrit.2021.08.001","type":"journal-article","created":{"date-parts":[[2021,8,20]],"date-time":"2021-08-20T06:26:36Z","timestamp":1629440796000},"page":"1331-1341","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":10,"title":["Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process"],"prefix":"10.1016","volume":"51","author":[{"given":"David","family":"Roofeh","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shaney L.","family":"Barratt","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Athol U","family":"Wells","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Leticia","family":"Kawano-Dourado","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Tashkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Vibeke","family":"Strand","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"James","family":"Seibold","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Susanna","family":"Proudman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kevin K","family":"Brown","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul F","family":"Dellaripa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tracy","family":"Doyle","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Thomas","family":"Leonard","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Eric L","family":"Matteson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chester V","family":"Oddis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joshua J","family":"Solomon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeffrey A","family":"Sparks","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robert","family":"Vassallo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lara","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dorcas","family":"Beaton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Robin","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Whitney","family":"Townsend","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dinesh","family":"Khanna","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"issue":"10103","key":"10.1016\/j.semarthrit.2021.08.001_bib0001","doi-asserted-by":"crossref","first-page":"1685","DOI":"10.1016\/S0140-6736(17)30933-9","article-title":"Systemic sclerosis","volume":"390","author":"Denton","year":"2017","journal-title":"Lancet"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.08.001_bib0002","doi-asserted-by":"crossref","first-page":"e329","DOI":"10.1016\/j.lpm.2014.08.002","article-title":"Interstitial lung disease in systemic sclerosis","volume":"43","author":"Wells","year":"2014","journal-title":"Press Medicale"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.08.001_bib0003","doi-asserted-by":"crossref","first-page":"940","DOI":"10.1136\/ard.2006.066068","article-title":"Changes in causes of death in systemic sclerosis, 1972-2002","volume":"66","author":"Steen","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.08.001_bib0004","doi-asserted-by":"crossref","first-page":"1809","DOI":"10.1136\/ard.2009.114264","article-title":"Causes and risk factors for death in systemic sclerosis: a study from the EULAR scleroderma trials and research (EUSTAR) database","volume":"69","author":"Tyndall","year":"2010","journal-title":"Ann Rheum Dis"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0005","doi-asserted-by":"crossref","DOI":"10.1097\/BOR.0000000000000270","article-title":"Management of connective tissue diseases associated interstitial lung disease: a review of the published literature","author":"Wallace","year":"2016","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0006","doi-asserted-by":"crossref","DOI":"10.1038\/nrrheum.2014.149","article-title":"Interstitial lung disease in connective tissue disease\u2014mechanisms and management","author":"Wells","year":"2014","journal-title":"Nat Rev Rheumatol"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0007","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s12931-019-0980-7","article-title":"Interstitial lung disease associated with systemic sclerosis (SSc-ILD)","volume":"20","author":"Cottin","year":"2019","journal-title":"Respir Res"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.08.001_bib0008","doi-asserted-by":"crossref","first-page":"1326","DOI":"10.1136\/annrheumdis-2018-213201","article-title":"Prediction of progression of interstitial lung disease in patients with systemic sclerosis: the SPAR model","volume":"77","author":"Wu","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.08.001_bib0009","doi-asserted-by":"crossref","first-page":"723","DOI":"10.1378\/chest.13-1474","article-title":"Predicting survival across chronic interstitial lung disease: the ILD-GAP model","volume":"145","author":"Ryerson","year":"2014","journal-title":"Chest"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.08.001_bib0010","doi-asserted-by":"crossref","first-page":"409","DOI":"10.1007\/s00408-018-0126-6","article-title":"Assessing mortality models in systemic sclerosis-related interstitial lung disease","volume":"196","author":"Mango","year":"2018","journal-title":"Lung"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0011","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1097\/BOR.0000000000000027","article-title":"Mortality in systemic sclerosis: lessons learned from population-based and observational cohort studies","volume":"26","author":"Nikpour","year":"2014","journal-title":"Curr Opin Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0012","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1055\/s-0039-1683431","article-title":"Systemic sclerosis associated interstitial lung disease: a comprehensive overview","volume":"40","author":"Mackintosh","year":"2019","journal-title":"Semin Respir Crit Care Med"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.08.001_bib0013","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1097\/BOR.0000000000000592","article-title":"Management of systemic sclerosis-associated interstitial lung disease","volume":"31","author":"Roofeh","year":"2019","journal-title":"Curr Opin Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0014","doi-asserted-by":"crossref","first-page":"137","DOI":"10.1111\/1756-185X.13799","article-title":"Management of systemic sclerosis-associated interstitial lung disease in the current era","volume":"23","author":"Amjadi","year":"2020","journal-title":"Int J Rheum Dis"},{"issue":"2 PG-","key":"10.1016\/j.semarthrit.2021.08.001_bib0015","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0016","doi-asserted-by":"crossref","first-page":"v27","DOI":"10.1093\/rheumatology\/kex203","article-title":"Interstitial lung disease points to consider for clinical trials in systemic sclerosis","volume":"56","author":"Khanna","year":"2017","journal-title":"Rheumatology (Oxford)"},{"issue":"2S","key":"10.1016\/j.semarthrit.2021.08.001_bib0017","doi-asserted-by":"crossref","first-page":"61","DOI":"10.1177\/2397198320903208","article-title":"Treatment of systemic sclerosis\u2013associated interstitial lung disease: lessons from clinical trials","volume":"5","author":"Roofeh","year":"2020","journal-title":"J Scleroderma Relat Disord"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0018","doi-asserted-by":"crossref","first-page":"1014","DOI":"10.3899\/jrheum.181097","article-title":"Core domain set selection according to OMERACT filter 2.1: the OMERACT methodology","volume":"46","author":"Maxwell","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0019","doi-asserted-by":"crossref","first-page":"1021","DOI":"10.3899\/jrheum.181096","article-title":"OMERACT filter 2.1: elaboration of the conceptual framework for outcome measurement in health intervention studies","volume":"46","author":"Boers","year":"2019","journal-title":"J Rheumatol"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.08.001_bib0020","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0021","series-title":"Interstitial lung disease","first-page":"87","article-title":"Approach to the diagnosis of interstitial lung disease","author":"Behr","year":"2018"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0022","series-title":"Clinical practice manual for pulmonary and critical care medicine","first-page":"22","article-title":"Pulmonary function testing","author":"Landsberg","year":"2018"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0023","unstructured":"Grippi MA, Tino G. Pulmonary Function Testing. In: Grippi MA, Elias JA, Fishman JA, Kotloff RM, Pack AI, Senior RM SM, ed.Fishman's Pulmonary Diseases and Disorders. 5th ed. New York; 2015."},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0024","unstructured":"O'Donnell D. Physiology of interstitial lung disease. In: Schwartz M, King T, eds. Interstitial Lung Disease.; 1998:51-70."},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0025","unstructured":"Scanlon PD. Respiratory function: mechanisms and testing. In: Goldman-Cecil Medicine. 25th ed.; 2016:539-545."},{"issue":"11","key":"10.1016\/j.semarthrit.2021.08.001_bib0026","doi-asserted-by":"crossref","first-page":"1463","DOI":"10.1164\/rccm.201710-1981ST","article-title":"Recommendations for a standardized pulmonary function report. an official american thoracic society technical statement","volume":"196","author":"Culver","year":"2017","journal-title":"Am J Respir Crit Care Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.08.001_bib0027","doi-asserted-by":"crossref","first-page":"1283","DOI":"10.1002\/art.1780370903","article-title":"Severe restrictive lung disease in systemic sclerosis","volume":"37","author":"Steen","year":"1994","journal-title":"Arthritis Rheum"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0028","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"148","key":"10.1016\/j.semarthrit.2021.08.001_bib0029","doi-asserted-by":"crossref","DOI":"10.1183\/16000617.0102-2017","article-title":"Pulmonary function tests as outcomes for systemic sclerosis interstitial lung disease","volume":"27","author":"Caron","year":"2018","journal-title":"Eur Respir Rev"},{"issue":"25","key":"10.1016\/j.semarthrit.2021.08.001_bib0030","doi-asserted-by":"crossref","first-page":"2655","DOI":"10.1056\/NEJMoa055120","article-title":"Cyclophosphamide versus placebo in scleroderma lung disease","volume":"354","author":"Tashkin","year":"2006","journal-title":"N Engl J Med"},{"issue":"9","key":"10.1016\/j.semarthrit.2021.08.001_bib0031","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1016\/S2213-2600(16)30152-7","article-title":"Mycophenolate mofetil versus oral cyclophosphamide in scleroderma-related interstitial lung disease (SLS II): a randomised controlled, double-blind, parallel group trial","volume":"4","author":"Tashkin","year":"2016","journal-title":"Lancet Respir Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0032","doi-asserted-by":"crossref","first-page":"138","DOI":"10.2174\/157339710791330768","article-title":"Systemic sclerosis-associated interstitial lung disease: lessons from clinical trials, outcome measures, and future study design","volume":"6","author":"Khanna","year":"2010","journal-title":"Curr Rheumatol Rev"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0033","first-page":"55","article-title":"Systemic sclerosis-associated interstitial lung disease - Proposed recommendations for future randomised clinical trials","volume":"28","author":"Khanna","year":"2010","journal-title":"Clin Exp Rheumatol"},{"issue":"SUPPL. 5","key":"10.1016\/j.semarthrit.2021.08.001_bib0034","first-page":"48","article-title":"Outcome measures in the lung","volume":"47","author":"Wells","year":"2009","journal-title":"Rheumatology"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0035","doi-asserted-by":"crossref","first-page":"948","DOI":"10.1183\/09031936.05.00035205","article-title":"Interpretative strategies for lung function tests","volume":"26","author":"Pellegrino","year":"2005","journal-title":"Eur Respir J"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0036","series-title":"Murray and Nadel's textbook of respiratory medicine","first-page":"407","article-title":"Pulmonary function testing","author":"Gold","year":"2016"},{"issue":"2 PG-374-81","key":"10.1016\/j.semarthrit.2021.08.001_bib0037","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2014-206076","article-title":"Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis","volume":"75","author":"Tashkin","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0038","doi-asserted-by":"crossref","first-page":"742","DOI":"10.1097\/00004728-199109000-00003","article-title":"Standardized quantitative high resolution ct in lung diseases","volume":"15","author":"Rienm\u00fcller","year":"1991","journal-title":"J Comput Assist Tomogr"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.08.001_bib0039","doi-asserted-by":"crossref","first-page":"720","DOI":"10.1183\/09031936.05.00034905","article-title":"Standardisation of the single-breath determination of carbon monoxide uptake in the lung","volume":"26","author":"MacIntyre","year":"2005","journal-title":"Eur Respir J"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.08.001_bib0040","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00010-2017","article-title":"Official ERS technical standards: global lung Function Initiative reference values for the carbon monoxide transfer factor for Caucasians","volume":"50","author":"Stanojevic","year":"2017","journal-title":"Eur Respir J"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.08.001_bib0041","doi-asserted-by":"crossref","first-page":"2168","DOI":"10.3899\/jrheum.141182","article-title":"Connective tissue disease-associated interstitial lung diseases (CTD-ILD) - report from OMERACT CTD-ILD working group","volume":"42","author":"Khanna","year":"2015","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0042","doi-asserted-by":"crossref","DOI":"10.3899\/jrheum.180441","article-title":"Cyclophosphamide for systemic sclerosis-related interstitial lung disease: a comparison of scleroderma lung study I and II","author":"Volkmann","year":"2019","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0043","doi-asserted-by":"crossref","first-page":"1028","DOI":"10.3899\/jrheum.181218","article-title":"Instrument selection using the OMERACT filter 2.1: the OMERACT methodology","volume":"46","author":"Beaton","year":"2019","journal-title":"J Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0044","series-title":"Statistics at square one","article-title":"Ch 11: Correlation and regression","author":"Swinscow","year":"1997"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0045","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1016\/j.jcm.2016.02.012","article-title":"A guideline of selecting and reporting intraclass correlation coefficients for reliability research","volume":"15","author":"Koo","year":"2016","journal-title":"J Chiropr Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0046","doi-asserted-by":"crossref","first-page":"420","DOI":"10.1037\/0033-2909.86.2.420","article-title":"Intraclass correlations: uses in assessing rater reliability","volume":"86","author":"Shrout","year":"1979","journal-title":"Psychol Bull"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0047","doi-asserted-by":"crossref","unstructured":"Liljequist D, Elfving B, Roaldsen KS.Intraclass Correlation \u2013 A Discussion and Demonstration of Basic Features. Vol 14.; 2019.","DOI":"10.1371\/journal.pone.0219854"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0048","doi-asserted-by":"crossref","first-page":"144","DOI":"10.6000\/1929-6029.2012.01.02.07","article-title":"On the measurement of change in medical research","volume":"1","author":"Luis","year":"2012","journal-title":"Int J Stat Med Res"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0049","doi-asserted-by":"crossref","first-page":"102","DOI":"10.1016\/j.jclinepi.2007.03.012","article-title":"Recommended methods for determining responsiveness and minimally important differences for patient-reported outcomes","volume":"61","author":"Revicki","year":"2008","journal-title":"J Clin Epidemiol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0050","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1164\/rccm.201709-1845OC","article-title":"Reliability and minimal clinically important differences of FVC results from the scleroderma lung studies (SLS-I and SLS-II)","volume":"197","author":"Kafaja","year":"2018","journal-title":"Am J Respir Crit Care Med"},{"issue":"7","key":"10.1016\/j.semarthrit.2021.08.001_bib0051","first-page":"1630","article-title":"Current status of outcome measure development for clinical trials in systemic sclerosis","volume":"30","author":"Merkel","year":"2003","journal-title":"J Rheumatol"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0052","doi-asserted-by":"crossref","first-page":"E70","DOI":"10.1164\/rccm.201908-1590ST","article-title":"Standardization of spirometry 2019 update an official American thoracic society and European respiratory society technical statement","volume":"200","author":"Graham","year":"2019","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0053","doi-asserted-by":"crossref","DOI":"10.1183\/13993003.00016-2016","article-title":"Executive summary: 2017 ERS\/ATS standards for single-breath carbon monoxide uptake in the lung","volume":"49","author":"Graham","year":"2017","journal-title":"Eur Respir J"},{"issue":"6","key":"10.1016\/j.semarthrit.2021.08.001_bib0054","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.5114\/aoms.2015.56352","article-title":"Causes and prevalence of inadequate pulmonary function testing among patients with systemic sclerosis","volume":"11","author":"Sumphao-Ngern","year":"2015","journal-title":"Arch Med Sci"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0055","doi-asserted-by":"crossref","first-page":"319","DOI":"10.1183\/09031936.05.00034805","article-title":"Standardisation of spirometry","volume":"26","author":"Miller","year":"2005","journal-title":"Eur Respir J"},{"issue":"9790","key":"10.1016\/j.semarthrit.2021.08.001_bib0056","doi-asserted-by":"crossref","first-page":"498","DOI":"10.1016\/S0140-6736(11)60982-3","article-title":"Autologous non-myeloablative haemopoietic stem-cell transplantation compared with pulse cyclophosphamide once per month for systemic sclerosis (ASSIST): an open-label, randomised phase 2 trial","volume":"378","author":"Burt","year":"2011","journal-title":"Lancet"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0057","doi-asserted-by":"crossref","DOI":"10.1016\/j.semarthrit.2016.10.003","article-title":"A multicenter, open-label, comparative study of B-cell depletion therapy with rituximab for systemic sclerosis-associated interstitial lung disease","author":"Daoussis","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"26","key":"10.1016\/j.semarthrit.2021.08.001_bib0058","doi-asserted-by":"crossref","first-page":"2518","DOI":"10.1056\/NEJMoa1903076","article-title":"Nintedanib for systemic sclerosis-associated interstitial lung disease","volume":"380","author":"Distler","year":"2019","journal-title":"N Engl J Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0059","doi-asserted-by":"crossref","first-page":"223","DOI":"10.1007\/s10067-010-1493-4","article-title":"A long-term prospective randomized controlled study of non-specific interstitial pneumonia (NSIP) treatment in scleroderma","volume":"30","author":"Domiciano","year":"2011","journal-title":"Clin Rheumatol"},{"issue":"4","key":"10.1016\/j.semarthrit.2021.08.001_bib0060","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/ar4606","article-title":"Low-dose oral imatinib in the treatment of systemic sclerosis interstitial lung disease unresponsive to cyclophosphamide: a phase II pilot study","volume":"16","author":"Fraticelli","year":"2014","journal-title":"Arthritis Res Ther"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.08.001_bib0061","doi-asserted-by":"crossref","first-page":"3962","DOI":"10.1002\/art.22204","article-title":"A multicenter, prospective, randomized, double-blind, placebo-controlled trial of corticosteroids and intravenous cyclophosphamide followed by oral azathioprine for the treatment of pulmonary fibrosis in scleroderma","volume":"54","author":"Hoyles","year":"2006","journal-title":"Arthritis Rheum"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.08.001_bib0062","doi-asserted-by":"crossref","first-page":"3540","DOI":"10.1002\/art.30548","article-title":"A one-year, phase I\/IIa, open-label pilot trial of imatinib mesylate in the treatment of systemic sclerosis-associated active interstitial lung disease","volume":"63","author":"Khanna","year":"2011","journal-title":"Arthritis Rheum"},{"issue":"2 PG-212-220","key":"10.1016\/j.semarthrit.2021.08.001_bib0063","doi-asserted-by":"crossref","first-page":"212","DOI":"10.1136\/annrheumdis-2017-211682","article-title":"Safety and efficacy of subcutaneous tocilizumab in systemic sclerosis: results from the open-label period of a phase II randomised controlled trial (faSScinate)","volume":"77","author":"Khanna","year":"2018","journal-title":"Ann Rheum Dis"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0064","first-page":"298","article-title":"Cyclophosphamide with low or high dose prednisolone for systemic sclerosis lung disease","volume":"29","author":"Pakas","year":"2002","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.08.001_bib0065","first-page":"2106","article-title":"Intravenous cyclophosphamide vs rituximab for the treatment of early diffuse scleroderma lung disease: Open label, randomized, controlled trial","volume":"57","author":"Sircar","year":"2018","journal-title":"Rheumatol (United Kingdom)"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0066","doi-asserted-by":"crossref","first-page":"35","DOI":"10.1056\/NEJMoa1703327","article-title":"Myeloablative autologous stem-cell transplantation for severe scleroderma","volume":"378","author":"Sullivan","year":"2018","journal-title":"N Engl J Med"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0067","doi-asserted-by":"crossref","DOI":"10.1186\/ar3125","article-title":"Predictors of interstitial lung disease in early systemic sclerosis: A prospective longitudinal study of the GENISOS cohort","author":"Assassi","year":"2010","journal-title":"Arthritis Res Ther"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0068","doi-asserted-by":"crossref","first-page":"644","DOI":"10.1136\/ard.2007.075721","article-title":"The relationship of dyspnoea to function and quality of life in systemic sclerosis","volume":"67","author":"Baron","year":"2008","journal-title":"Ann Rheum Dis"},{"issue":"2 PG-169-73","key":"10.1016\/j.semarthrit.2021.08.001_bib0069","first-page":"169","article-title":"Submaximal exercise testing in the assessment of interstitial lung disease secondary to systemic sclerosis: reproducibility and correlations of the 6-min walk test","volume":"66","author":"Buch","year":"2007","journal-title":"Ann Rheum Dis"},{"issue":"11 PG-1248-54","key":"10.1016\/j.semarthrit.2021.08.001_bib0070","doi-asserted-by":"crossref","first-page":"1248","DOI":"10.1164\/rccm.200706-877OC","article-title":"Interstitial lung disease in systemic sclerosis: a simple staging system","volume":"177","author":"Goh","year":"2008","journal-title":"Am J Respir Crit Care Med"},{"issue":"8 PG-1670-1678","key":"10.1016\/j.semarthrit.2021.08.001_bib0071","doi-asserted-by":"crossref","first-page":"1670","DOI":"10.1002\/art.40130","article-title":"Short-term pulmonary function trends are predictive of mortality in interstitial lung disease associated with systemic sclerosis","volume":"69","author":"Goh","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0072","doi-asserted-by":"crossref","first-page":"358","DOI":"10.1378\/chest.07-2444","article-title":"High-resolution CT scan findings in patients with symptomatic scleroderma-related interstitial lung disease","volume":"134","author":"Goldin","year":"2008","journal-title":"Chest"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0073","doi-asserted-by":"crossref","first-page":"1333","DOI":"10.1378\/chest.09-0108","article-title":"Treatment of scleroderma-interstitial lung disease with cyclophosphamide is associated with less progressive fibrosis on serial thoracic high-resolution CT scan than placebo: findings from the scleroderma lung study","volume":"136","author":"Goldin","year":"2009","journal-title":"Chest"},{"issue":"Suppl 10","key":"10.1016\/j.semarthrit.2021.08.001_bib0074","article-title":"Changes in quantitative scleroderma lung CT measures in patients treated with cyclophosphamide or transplantation","volume":"70","author":"Goldin","year":"2018","journal-title":"Arthritis Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.08.001_bib0075","doi-asserted-by":"crossref","first-page":"1427","DOI":"10.1513\/AnnalsATS.201806-362OC","article-title":"Does systemic sclerosis-associated interstitial lung disease burn out?\u00a0:specific phenotypes of disease progression","volume":"15","author":"Guler","year":"2018","journal-title":"Ann Am Thorac Soc"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0076","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.semarthrit.2017.03.019","article-title":"Clinical algorithms for the diagnosis and prognosis of interstitial lung disease in systemic sclerosis","volume":"47","author":"Hax","year":"2017","journal-title":"Semin Arthritis Rheum"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0077","doi-asserted-by":"crossref","first-page":"2205","DOI":"10.1002\/art.39166","article-title":"Predictive value of serial high-resolution computed tomography analyses and concurrent lung function tests in systemic sclerosis","volume":"67","author":"Hoffmann-Vold","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0078","first-page":"832","article-title":"Responsiveness of the SF-36 and the health assessment questionnaire disability index in a systemic sclerosis clinical trial","volume":"32","author":"Khanna","year":"2005","journal-title":"J Rheumatol"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.08.001_bib0079","doi-asserted-by":"crossref","first-page":"1537","DOI":"10.1093\/rheumatology\/kep284","article-title":"Minimally important differences in the Mahler's Transition Dyspnoea Index in a large randomized controlled trial - Results from the scleroderma lung study","volume":"48","author":"Khanna","year":"2009","journal-title":"Rheumatology"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0080","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s13075-015-0872-2","article-title":"Predictors of lung function decline in scleroderma-related interstitial lung disease based on high-resolution computed tomography: Implications for cohort enrichment in systemic sclerosis-associated interstitial lung disease trials","volume":"17","author":"Khanna","year":"2015","journal-title":"Arthritis Res Ther"},{"issue":"1 PG-155-60","key":"10.1016\/j.semarthrit.2021.08.001_bib0081","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1093\/rheumatology\/kes289","article-title":"Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease","volume":"52","author":"Moore","year":"2013","journal-title":"Rheumatol"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0082","first-page":"111","article-title":"Quantifying change in pulmonary function as a prognostic marker in systemic sclerosis-related interstitial lung disease","volume":"33","author":"Moore","year":"2015","journal-title":"Clin Exp Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0083","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1016\/j.chest.2017.06.009","article-title":"Mortality risk prediction in scleroderma-related interstitial lung disease: the SADL model","volume":"152","author":"Morisset","year":"2017","journal-title":"Chest"},{"key":"10.1016\/j.semarthrit.2021.08.001_bib0084","first-page":"3","article-title":"Can patient-reported symptoms be used to measure disease activity in systemic sclerosis?","author":"Ross","year":"2019","journal-title":"Arthritis Care Res (Hoboken)"},{"issue":"1","key":"10.1016\/j.semarthrit.2021.08.001_bib0085","doi-asserted-by":"crossref","first-page":"2797","DOI":"10.1002\/art.30438","article-title":"Predicting treatment outcomes and responder subsets in scleroderma-related interstitial lung disease","volume":"23","author":"Roth","year":"2011","journal-title":"Arthritis Rheumatol"},{"issue":"5","key":"10.1016\/j.semarthrit.2021.08.001_bib0086","doi-asserted-by":"crossref","first-page":"1268","DOI":"10.1378\/chest.15-0003","article-title":"Predicting mortality in systemic sclerosis-associated interstitial lung disease using risk prediction models derived from idiopathic pulmonary fibrosis","volume":"148","author":"Ryerson","year":"2015","journal-title":"Chest"},{"issue":"3","key":"10.1016\/j.semarthrit.2021.08.001_bib0087","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1371\/journal.pone.0149240","article-title":"Computer-aided tomographic analysis of interstitial lung disease (ILD) in patients with systemic sclerosis (SSc). Correlation with pulmonary physiologic tests and patient-centred measures of perceived dyspnea and functional disability","volume":"11","author":"Salaffi","year":"2016","journal-title":"PLoS One"},{"issue":"11","key":"10.1016\/j.semarthrit.2021.08.001_bib0088","doi-asserted-by":"crossref","first-page":"1572","DOI":"10.3899\/jrheum.171362","article-title":"Performance of forced vital capacity and lung diffusion cutpoints for associated radiographic interstitial lung disease in systemic sclerosis","volume":"45","author":"Showalter","year":"2018","journal-title":"J Rheumatol"},{"issue":"11 PG-1984-91","key":"10.1016\/j.semarthrit.2021.08.001_bib0089","doi-asserted-by":"crossref","first-page":"1984","DOI":"10.1002\/art.1780401110","article-title":"The value of the health assessment questionnaire and special patient-generated scales to demonstrate change in systemic sclerosis patients over time","volume":"40","author":"Steen","year":"1997","journal-title":"Arthritis Rheum"},{"issue":"12","key":"10.1016\/j.semarthrit.2021.08.001_bib0090","doi-asserted-by":"crossref","first-page":"3256","DOI":"10.1002\/art.39405","article-title":"Pulmonary function tests: high rate of false-negative results in the early detection and screening of scleroderma-related interstitial lung disease","volume":"67","author":"Suliman","year":"2015","journal-title":"Arthritis Rheumatol"},{"issue":"10","key":"10.1016\/j.semarthrit.2021.08.001_bib0091","doi-asserted-by":"crossref","first-page":"1026","DOI":"10.1164\/rccm.200702-326OC","article-title":"Effects of 1-year treatment with cyclophosphamide on outcomes at 2 years in scleroderma lung disease","volume":"176","author":"Tashkin","year":"2007","journal-title":"Am J Respir Crit Care Med"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0092","doi-asserted-by":"crossref","first-page":"374","DOI":"10.1136\/annrheumdis-2014-206076","article-title":"Relationship between quantitative radiographic assessments of interstitial lung disease and physiological and clinical features of systemic sclerosis","volume":"75","author":"Tashkin","year":"2016","journal-title":"Ann Rheum Dis"},{"issue":"4 PG-813-820","key":"10.1016\/j.semarthrit.2021.08.001_bib0093","doi-asserted-by":"crossref","first-page":"813","DOI":"10.1016\/j.chest.2016.11.052","article-title":"Improved cough and cough-specific quality of life in patients treated for scleroderma-related interstitial lung disease: results of scleroderma lung study II","volume":"151","author":"Tashkin","year":"2017","journal-title":"Chest"},{"issue":"3 PG-614-621","key":"10.1016\/j.semarthrit.2021.08.001_bib0094","doi-asserted-by":"crossref","first-page":"614","DOI":"10.1378\/chest.11-0801","article-title":"Correlation of cough with disease activity and treatment with cyclophosphamide in scleroderma interstitial lung disease: findings from the scleroderma lung study","volume":"142","author":"Theodore","year":"2012","journal-title":"Chest"},{"issue":"2","key":"10.1016\/j.semarthrit.2021.08.001_bib0095","first-page":"6072","article-title":"Development of a composite outcome measure for systemic sclerosis related interstitial lung disease","volume":"5","author":"Volkmann","year":"2015","journal-title":"Rheumatology"},{"issue":"7 PG-1451-1460","key":"10.1016\/j.semarthrit.2021.08.001_bib0096","doi-asserted-by":"crossref","first-page":"1451","DOI":"10.1002\/art.40114","article-title":"Mycophenolate mofetil versus placebo for systemic sclerosis-related interstitial lung disease: an analysis of scleroderma lung studies I and II","volume":"69","author":"Volkmann","year":"2017","journal-title":"Arthritis Rheumatol"},{"issue":"1 PG-122-130","key":"10.1016\/j.semarthrit.2021.08.001_bib0097","doi-asserted-by":"crossref","first-page":"122","DOI":"10.1136\/annrheumdis-2018-213708","article-title":"Short-term progression of interstitial lung disease in systemic sclerosis predicts long-term survival in two independent clinical trial cohorts","volume":"78","author":"Volkmann","year":"2019","journal-title":"Ann Rheum Dis"},{"issue":"8","key":"10.1016\/j.semarthrit.2021.08.001_bib0098","first-page":"1369","article-title":"Reliability, validity and responsiveness to change of the Saint George'S Respiratory Questionnaire in early diffuse cutaneous systemic sclerosis","volume":"54","author":"Wallace","year":"2015","journal-title":"Rheumatol (United Kingdom)"}],"container-title":["Seminars in Arthritis and Rheumatism"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001554?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0049017221001554?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2023,11,7]],"date-time":"2023-11-07T16:46:53Z","timestamp":1699375613000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0049017221001554"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":98,"journal-issue":{"issue":"6","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["S0049017221001554"],"URL":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.001","relation":{},"ISSN":["0049-0172"],"issn-type":[{"value":"0049-0172","type":"print"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Outcome measurement instrument selection for lung physiology in systemic sclerosis associated interstitial lung disease: A systematic review using the OMERACT filter 2.1 process","name":"articletitle","label":"Article Title"},{"value":"Seminars in Arthritis and Rheumatism","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.semarthrit.2021.08.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2021 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}